(Q33362032)

English

Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

ovarian carcinoma

1 reference

based on heuristic

inferred from title

author name string

Sundar S

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Symonds RP

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Decatris MP

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kumar DM

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Osman A

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Vasanthan S

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

O'byrne KJ

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 August 2004

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

94

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

502-508

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Cancer of the ovary

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Second-line treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

cis-platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumour cells from patients receiving high dose cis-platinum as first line treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Long-term survival rates with various chemotherapeutic regimens in stages III and IV ovarian adenocarcinoma. The influence of optimum pretreatment surgical resection

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Building a Taxonomy and Nomenclature of Collaborative Writing to Improve Interdisciplinary Research and Practice

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

CA125 response: can it replace the traditional response criteria in ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Expression of the thymidine phosphorylase gene in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

5-fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma. A phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.04.020

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.YGYNO.2004.04.020

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33362032&oldid=1946472507"